Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 2011

View Archived Issues

Phase I study of JVS-100 complete

First-in-human results presented on PRS-050 in patients with advanced solid malignancies

Costimulatory fusion protein enhances activity of tumor vaccine in vivo

Takeda presents new antiatherosclerotic compounds

Preclinical study assesses antitumor effects of Pfizer's new antibody-drug conjugate

Medunik Canada acquires Canadian rights to two orphan therapies from QOL Medical

Idera Pharmaceuticals obtains FDA authorization for IMO-3100 trial

Anthera Pharmaceuticals completes interim analysis of PEARL-SC study

Novel PI3K and mTOR inhibitors patented by Spanish researchers

XTL Biopharmaceuticals acquires MinoGuard

New apoptosis inhibitors described in Chinese PLA General Hospital patent

Evotec patents novel orexin OX2 receptor antagonists

New beta-secretase inhibitors discovered by Roche and Siena Biotech

Octagam 5% now available again in the U.S.

Novel caspase-3 activators and apoptosis inducers reported in patent literature

NovaBay advances phase II NVC-422 study

FDA grants orphan drug designation to Emergent's TRU-016

Curis and the Leukemia and Lymphoma Society agree to develop CUDC-907

Ceregene completes enrollment in second phase II CERE-120 study

Auxilium Pharmaceuticals doses first patient in Xiaflex study

Brewer Sports International to fund traumatic brain injury research

MacroGenics and Servier enter into license agreement for MGA-271

Celldex Therapeutics begins phase III trial of rindopepimut

Generex provides update on clinical and regulatory status of buccal insulin spray

NPS Pharmaceuticals files NDA seeking FDA approval of Gattex

EMA approves combination antimalarial drug Eurartesim

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...